Soc. Generale Call 140 MRK 19.12..../ DE000SY7A0L6 /
11/11/2024 17:58:10 | Var.-0.020 | Denaro18:40:49 | Lettera18:40:49 | Sottostante | Prezzo di esercizio | Expiration date | Tipo di opzione |
---|---|---|---|---|---|---|---|
0.230EUR | -8.00% | 0.230 Quantità in denaro: 225,000 |
0.240 Quantità in lettera: 225,000 |
Merck and Co Inc | 140.00 USD | 19/12/2025 | Call |
GlobeNewswire
31/07
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire
17/07
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
11/06
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
06/06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
28/05
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
GlobeNewswire
23/05
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
GlobeNewswire
16/05
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
14/05
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
08/05
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
24/04
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Onc...
GlobeNewswire
15/04
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness